

Provided by:



## Allogeneic Stem Cell Transplantation Rounds 2023-2024

**Allogeneic Stem Cell Transplantation Rounds 2023-2024 - 6/1/2023**

**June 1, 2023**

**1:00 PM - 2:00 PM**

**Perelman Center for Advanced Medicine, Conference Room 12-122**

### Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Identify and discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors. Patient selection will require consideration of many of these disease factors.
- 2 Describe the likelihood of developing C. difficile as well as methods to prevent transmission, the unique risks associated with this infection in transplant patients, and list methods that prevent infection including how practice changes effect outcomes.
- 3 Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS, including an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches
- 4 Describe differences and potential risks and benefits associated with different donor choices from an interprofessional perspective with an emphasis on developing a consistent approach to donor selection through systematic evaluation of various options.

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is approved for **1.00** contact hours  
UAN Number: JA0000324-0000-23-032-L04-P

For more information, please contact  
**Amanda Barefield, Tamiesshia Nixon, Julie Mcdaniel**  
**(215) 662-2867, (215) 662-4074, (267) 970-8367**  
**amanda.barefield@penntmedicine.upenn.edu, Tamiesshia.Nixon@penntmedicine.upenn.edu,**  
**mcdjulie@upenn.edu**

**Check your transcript online at <https://upenn.cloud-cme.com>**

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

**Disclosure of Relevant Financial Relationships and Unapproved Uses of Products**

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Alison W Loren, MD, MSCE	Co-Director, Faculty	Nothing to disclose - 04/18/2023
David L Porter, MD	Course Director	Stocks or stock options, excluding diversified mutual funds-Genentech   Honoraria-Novartis (Advanced Health Media) (Relationship has ended)   Honoraria-Bristol-Myers Squibb (Relationship has ended)   Honoraria-Gilead Sciences, Inc (Relationship has ended)   Honoraria-Janssen Pharmaceuticals (J&J) (Relationship has ended)   Honoraria-Jazz (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-DeCART (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bluebird Bio (Relationship has ended)   Honoraria-Kadmon (Relationship has ended)   Grant or research support-Novartis (Advanced Health Media)   Royalties or Patent Beneficiary-Novartis (Advanced Health Media)   Royalties or Patent Beneficiary-Tmunity (Relationship has ended)   Honoraria-Wiley publishing   Honoraria-Am Society for

		Transplant and Cell Therapy  Advisor-Angiocrine  Advisor-Mirror Biologics  Advisor-Capstan (Relationship has ended)  Advisor-Instill (Relationship has ended) - 03/03/2023
Jacqueline Smith, CRNP	Nurse Planner	Nothing to disclose - 11/29/2022
Noelle V. Frey, MD, MSCE	Other Planning Committee Member	Consulting Fee-Kite Pharma (Relationship has ended)  Consulting Fee-Sana Biotechnology (Relationship has ended) - 01/19/2023
Elizabeth Hexner, MD	Other Planning Committee Member	Grant or research support-Tmunity Therapeutics  Advisor-AbbVie, Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.- Blueprint Medicines  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pharmessentia (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine - 02/01/2023
Selina Luger, MD	Other Planning Committee Member	Honoraria-Bristol-Myers Squibb (Relationship has ended)  Honoraria-Celgene Corporation (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Marker - 02/06/2023
Mary Ellen Martin, MD	Other Planning Committee Member	Nothing to disclose - 01/27/2023
Alexander E Perl, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc.   Advisor-Immunogen (Relationship has ended)  Advisor-BerGenBio (Relationship has ended)  Advisor-Actinium (Relationship has ended)  Consulting Fee-Astellas  Consulting Fee-Foghorn  Advisor-Bristol-Myers Squibb (Relationship has ended)  Advisor-Genentech  Consulting Fee-Daiichi Sankyo   Advisor-Loxo (Relationship has ended)  Advisor-Syndax (Relationship has ended)  Consulting Fee-Sumitomo Dainippon (Relationship has ended)  Consulting Fee-Forma (Relationship has ended)  Consulting Fee-Leukemia and Lymphoma Society/BeatAML LLC  Grant or research support-AbbVie, Inc.   Grant or research support-Astellas  Grant or research support-Daiichi Sankyo  Grant or research support-Syndax  Grant or research support-FujiFilm (Relationship has ended) - 02/09/2023
Keith Pratz, MD	Other Planning Committee Member	Advisor-AbbVie, Inc.   Advisor-Bristol-Myers Squibb (Relationship has ended)  Advisor-Novartis / Amgen (Relationship has

		ended)  Advisor-Jazz Pharmaceuticals (Relationship has ended)  Advisor-Astellas (Relationship has ended)  Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)  Advisor-Roche (Relationship has ended) - 01/31/2023
Alison Carulli, PharmD	Pharmacy Planner	Nothing to disclose - 11/22/2022
Linda Perry, PA-C	Physician Assistant Planner	Paid consultant-Kadmon (Relationship has ended)  Speakers Bureau-Sanofi Genzyme  Paid consultant-Sanofi Genzyme  Speakers Bureau-AbbVie, Inc. (Relationship has ended)  Paid consultant-Incyte Corporation  Speakers Bureau-Incyte Corporation - 01/10/2023

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.